Description: Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Home Page: www.madrigalpharma.com
Four Tower Bridge
West Conshohocken,
PA
19428
United States
Phone:
267 824 2827
Officers
| Name | Title |
|---|---|
| Mr. William J. Sibold | CEO, President & Director |
| Dr. Rebecca A. Taub M.D. | Founder, Chief Medical Officer, President of Research & Development and Director |
| Ms. Carole Huntsman | Chief Commercial Officer |
| Ms. Mardi C. Dier | CFO & Senior VP |
| Mr. Mark Underwood | Senior Vice President of Business Planning & Operations |
| Mr. Ronald Filippo | Chief Information Officer |
| Ms. Tina E. Ventura | Chief Investor Relations Officer |
| Ms. Shannon Kelley | Chief Compliance Office & General Counsel |
| Mr. Clint Wallace | Chief Human Resources Officer |
| Mr. Edward Chiang | Senior Vice President of Clinical & Technical Operations |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.9775 |
| Price-to-Sales TTM: | 85.8071 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 376 |